0
0 (0%)
Sigyn Therapeutics, Inc. [RGNP]
Source:
Company Overview
Sigyn Therapeutics, Inc. developsmedical devices to treat cancer and infectious disease disorders. We believe our lineup of therapeutic candidates is among the most expansivein the field of extracorporeal blood purification.
| Country | United States |
| Headquarters | beverly hills, california |
| Phone Number | 619-368-2000 |
| Industry | manufacturing |
| CEO | James Joyce |
| Website | https://www.sigyntherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-2.5 |
| Net Income | $-3.3 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -1,247.5% |
| Profit as % of Stockholder Equity | 74.9% |
Management Effectiveness
| Return on Equity | 74.9% |
| Return on Assets | -1,562.9% |
| Turnover Ratio | |
| EBITA | $-2.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $0.2 |
| Total Liabilities | $4.7 |
| Operating Cash Flow | $-0.9 |
| Investing Cash Flow | |
| Financing Cash Flow | $0.9 |
